NeoGenomics, Inc. (NASDAQ:NEO) Receives $11.86 Consensus PT from Analysts

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have received a consensus recommendation of “Hold” from the fourteen research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $11.8571.

Several analysts recently issued reports on NEO shares. Zacks Research cut shares of NeoGenomics from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 20th. William Blair restated a “market perform” rating on shares of NeoGenomics in a report on Monday, March 16th. Weiss Ratings restated a “sell (d-)” rating on shares of NeoGenomics in a research report on Monday, December 29th. Benchmark reaffirmed a “hold” rating on shares of NeoGenomics in a report on Wednesday, February 18th. Finally, UBS Group reiterated a “hold” rating on shares of NeoGenomics in a research report on Wednesday, February 18th.

NeoGenomics Trading Down 3.0%

Shares of NEO opened at $7.86 on Friday. NeoGenomics has a 52-week low of $4.72 and a 52-week high of $13.74. The stock has a market cap of $1.02 billion, a PE ratio of -9.36 and a beta of 1.62. The firm’s fifty day moving average is $10.56 and its two-hundred day moving average is $10.51. The company has a quick ratio of 3.94, a current ratio of 4.26 and a debt-to-equity ratio of 0.41.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, February 17th. The medical research company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The business had revenue of $190.17 million during the quarter, compared to analysts’ expectations of $188.25 million. NeoGenomics had a negative net margin of 14.85% and a negative return on equity of 3.10%. The company’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.04 earnings per share. Research analysts forecast that NeoGenomics will post -0.2 earnings per share for the current fiscal year.

Insider Transactions at NeoGenomics

In other NeoGenomics news, COO Warren Stone sold 22,128 shares of the firm’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $12.50, for a total value of $276,600.00. Following the completion of the sale, the chief operating officer directly owned 121,631 shares of the company’s stock, valued at $1,520,387.50. This trade represents a 15.39% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On NeoGenomics

A number of hedge funds have recently modified their holdings of NEO. Royal Bank of Canada increased its position in NeoGenomics by 51.2% during the first quarter. Royal Bank of Canada now owns 56,026 shares of the medical research company’s stock worth $532,000 after purchasing an additional 18,966 shares during the last quarter. AQR Capital Management LLC acquired a new position in NeoGenomics in the 1st quarter valued at about $271,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of NeoGenomics by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 75,798 shares of the medical research company’s stock valued at $719,000 after buying an additional 3,254 shares during the period. Intech Investment Management LLC increased its holdings in shares of NeoGenomics by 19.7% during the 1st quarter. Intech Investment Management LLC now owns 151,806 shares of the medical research company’s stock worth $1,441,000 after buying an additional 24,965 shares during the last quarter. Finally, Savant Capital LLC acquired a new stake in shares of NeoGenomics during the 2nd quarter worth approximately $125,000. Hedge funds and other institutional investors own 98.50% of the company’s stock.

NeoGenomics Company Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.